A successful case of anti-NMDAR encephalitis without tumor treated with a prolonged regimen of plasmapheresis.

Autor:	Simabukuro MM; Neurology Department, Hospital Samaritano, São Paulo, Brazil.; Neurology Department, Hospital das Clínicas of the University of São Paulo School of Medicine (HCFMUSP), São Paulo, Brazil., Watanabe RGS; Neurology Department, Hospital Samaritano, São Paulo, Brazil.; Neurology Department, Hospital das Clínicas of the University of São Paulo School of Medicine (HCFMUSP), São Paulo, Brazil., Pinto LF; Neurology Department, Hospital Samaritano, São Paulo, Brazil.; Neurology Department, Hospital das Clínicas of the University of São Paulo School of Medicine (HCFMUSP), São Paulo, Brazil., Guariglia C; Neurology Department, Hospital das Clínicas of the University of São Paulo School of Medicine (HCFMUSP), São Paulo, Brazil., Gonçalves DCME; Neurology Department, Hospital Samaritano, São Paulo, Brazil.; Infectology Department, Hospital Samaritano, São Paulo, Brazil., Anghinah R; Neurology Department, Hospital Samaritano, São Paulo, Brazil.; Neurology Department, Hospital das Clínicas of the University of São Paulo School of Medicine (HCFMUSP), São Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	Dementia & neuropsychologia [Dement Neuropsychol] 2014 Jan-Mar; Vol. 8 (1), pp. 87-89.
DOI:	10.1590/S1980-57642014DN81000014
Abstrakt:	Anti-NMDA receptor encephalitis is a severe but treatable autoimmune disease of the CNS. However, the use of immunotherapy and long-term outcomes have yet to be defined for this disease. We describe a case of an 18-year-old male diagnosed with anti-NMDAR encephalitis not associated with tumor, which did not respond to initial treatment with immunoglobulin, followed by corticosteroids, cyclophosphamide and evolved with significant clinical improvement after a prolonged course of plasmapheresis. Although it is not possible to affirm the good outcome was due solely to the prolonged plasmapheresis regimen, recently published data shows that improvement may take weeks or months to occur. This case discloses another therapeutic possibility for patients with refractory disease who fail to respond to recommended first-line and second-line therapy. Competing Interests: Disclosure: The authors report no conflicts of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu